Annualised bleed rate among haemophilia A patients was significantly lower in real-world setting
News
NHS leaders voice stark staff warning
Changes to vocational BTEC healthcare qualifications could see reduction in new nurse recruits
VisionHealth and Boehringer Ingelheim link up for asthma
The partnership will deliver digital therapy support for asthma and COPD patients
Healx has new location at Chesterford Research Park
The lab will allow the Healx team to accelerate the discovery of potential new therapies for more rare conditions
Novo Nordisk release results from haemophilia treatment study
Data shows a significant reduction in treated spontaneous and traumatic bleeds among haemophilia patients
Sanofi and Sobi present effective bleeding treatment
Data demonstrates that efanesoctocog alfa provides superior bleed protection
NICE recommends Opdivo as post-surgery treatment
The therapy will be used for specific muscle invasive urothelial cancer patients
VarmX to present new data at the ISTH Congress
Preclinical data package details pharmacology and safety of VMX-C001
Diabetes patients to benefit from £10m heart disease data investment
The British Heart Foundation’s project will accelerate the search for better prevention and treatment of diabetes
NICE recommend’s use of Leo Pharma’s Adtralza
The therapy is for moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic treatment
NICE recommends Janssen’s treatment for active psoriatic arthritis
Clinical trial evidence suggests that Tremfya is effective when compared with a placebo
Touchlight signs patent agreement with Pfizer
Deal involves the manufacturing of mRNA-based vaccines, therapeutics and gene therapies
AlzeCure’s Alzheimer’s candidate shows promise
Treatment abstract focuses on results from a multiple ascending dose study in healthy volunteers
Bloom’s smart CRP test gets green light
C-Reactive protein test gets go-ahead for professional use across Europe
Advanz finalises acquisition of Intercept operations across Europe and Canada
The deal will give Advanz an increased presence in the treatment of rare diseases
